| Schedule of Financial Information Operating Segment |
The
following table presents selected financial information with respect to the Company’s single operating segment and its significant
segment expenses for the three months ended September 30, 2025 and 2024:
Schedule
of Financial Information Operating Segment
| |
|
2025 |
|
|
2024 |
|
| |
|
September 30, |
|
| |
|
2025 |
|
|
2024 |
|
| Pre-clinical and clinical studies |
|
$ |
406,912 |
|
|
$ |
833,861 |
|
| Contract manufacturing |
|
|
120,585 |
|
|
|
215,466 |
|
| Consultants and other research and development |
|
|
282,494 |
|
|
|
265,532 |
|
| Compensation and related benefits |
|
|
321,336 |
|
|
|
306,613 |
|
| Professional and consultant fees |
|
|
710,194 |
|
|
|
315,794 |
|
| Stock-based compensation expense |
|
|
237,644 |
|
|
|
286,920 |
|
| Directors’ and officers’ insurance |
|
|
110,329 |
|
|
|
117,158 |
|
| Facilities, fees and other related costs |
|
|
70,766 |
|
|
|
70,780 |
|
| Interest expense |
|
|
17,439 |
|
|
|
59,697 |
|
| Interest income |
|
|
(109,616 |
) |
|
|
(26,006 |
) |
| Grant income |
|
|
(9,825 |
) |
|
|
(245,362 |
) |
| Other |
|
|
96 |
|
|
|
283 |
|
| Net loss |
|
$ |
(2,158,354 |
) |
|
$ |
(2,200,736 |
) |
|